LAVA Therapeutics BV (LVTX): Price and Financial Metrics
LVTX Price/Volume Stats
Current price | $0.94 | 52-week high | $6.47 |
Prev. close | $0.93 | 52-week low | $0.85 |
Day low | $0.92 | Volume | 7,900 |
Day high | $0.94 | Avg. volume | 64,167 |
50-day MA | $1.08 | Dividend yield | N/A |
200-day MA | $1.76 | Market Cap | 24.71M |
LVTX Stock Price Chart Interactive Chart >
LAVA Therapeutics BV (LVTX) Company Bio
Lava Therapeutics B.V., a biotechnology company, engages in developing a portfolio of bispecific gamma-delta T cell engagers (gamma-delta bsTCEs) for the treatment of solid tumors and hematologic malignancies based on its platform. Its lead product candidate, LAVA-051, is advancing toward a Phase 1/2a clinical trial for the treatment of CD1d-expressing hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, and acute myeloid leukemia. The company also develops its gamma-delta bsTCEs in solid tumors, which targets prostate-specific membrane antigen for the treatment of prostate cancer. Lava Therapeutics B.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of potential product candidates
LVTX Price Returns
1-mo | 0.00% |
3-mo | -42.33% |
6-mo | -48.07% |
1-year | -56.48% |
3-year | -80.29% |
5-year | N/A |
YTD | -1.16% |
2024 | -39.81% |
2023 | -54.86% |
2022 | -36.36% |
2021 | N/A |
2020 | N/A |
Loading social stream, please wait...